IP Library Patent Application 13165101
Patent Application
App. No. 13/165,101

Antimicrobial Collagenous Constructs

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/165,101
Abstract

Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed.

Claims (20)

1 . A bioengineered collagen construct comprising:

a layer of purified collagenous tissue matrix derived from the tunica submucosa of a small intestine, said purified collagenous tissue matrix having been treated with an antimicrobial agent.

2 . The bioengineered collagen construct of claim 1 wherein the construct is meshed, fenestrated, or perforated.

3 . The bioengineered collagen construct of claim 2 wherein the mesh ratio of the mesh is 1:1.5.

4 . The bioengineered collagen construct of claim 1 wherein the antimicrobial agent is selected from the group consisting of nanocrystalline silver, silver oxide, silver nitrate, silver sulfazidine, silver-imidazolate, arglaes (AgKaPO 4 ), Poly(hexamethylene biguanide) hydrochloride (PHMB), chlorhexadine gluconate, bis-amido polybiguanides, honey, berizalkonium chloride, triclosan (2, 4, 4′-tricloro-2′-hydroxydiphenylether), and silyl quarternary ammonium salt (octadecyl demethyl trimethoxysilyl propyl ammonium chloride).

5 . The bioengineered collagen construct of claim 1 wherein the construct is crosslinked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.

6 - 24 . (canceled)

25 . A method of repairing or replacing a damaged tissue comprising the steps of:

implanting a prosthesis in a patient, said method comprising two or more superimposed, bonded layers of collagen material treated with an antimicrobial agent, wherein the prosthesis, when implanted at into a mammalian patient, undergoes controlled biodegradation occurring with adequate living cell replacement such that the implanted prosthesis is remodeled by the patient's living cells.

26 . The method of claim 25 , wherein the prosthesis comprises two to five sheets of processed intestinal collagen derived from the tunica submucosa of small intestine, said sheets being bonded and crosslinked together with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride at a concentration between 0.1 to 100 mM.

27 . The method of claim 25 , wherein the prosthesis comprises two to ten sheets of processed intestinal collagen derived from the tunica submucosa of small intestine, said sheets being bonded and crosslinked together with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride at a concentration between 0.1 to 100 mM.

28 . The method of claim 25 , wherein the prosthesis is a hernia repair patch, a femoral hernia repair plug, a pericardial patch, a bladder sling, a uterus sling, intracardiac patch, replacement heart valve, a vascular patch, an annular fibrosis repair plug, an annular fibrosis repair patch, a rotator cuff repair prosthesis, a dura mater repair patch, a cystocele repair device, a retrocele repair device, a vaginal vault prolapse repair sling, or a plastic surgery implant.

29 . A modified intestinal collagen layer comprising an intestinal collagen layer derived from the tunica submucosa of a small intestine, said layer having been treated with an antimicrobial agent.

30 . The modified intestinal collagen layer of claim 29 , wherein said antimicrobial agent is selected from the group consisting of nanocrystalline silver, silver oxide, silver nitrate, silver sulfazidine, silver-imidazolate, arglaes (AgKaPO 4 ), Poly(hexamethylene biguanide) hydrochloride (PHMB), chlorhexadine gluconate, bis-amido polybiguanides, honey, berizalkonium chloride, triclosan (2, 4, 4′-tricloro-2′-hydroxydiphenylether), and silyl quarternary ammonium salt (octadecyl demethyl trimethoxysilyl propyl ammonium chloride).

31 . The modified intestinal collagen layer of claim 30 , wherein the nanocrystalline silver lacks atomic disorder.

32 . (canceled)

33 . A processed tissue matrix comprising a mammalian cellular tissue substantially free of non-collagenous components, said processed tissue matrix having been treated with an antimicrobial agent.

34 . The processed tissue matrix of claim 33 , wherein said antimicrobial agent is selected from the group consisting of nanocrystalline silver, silver oxide, silver nitrate, silver sulfazidine, silver-imidazolate, arglaes (AgKaPO 4 ), Poly(hexamethylene biguanide) hydrochloride (PHMB), chlorhexadine gluconate, bis-amido polybiguanides, honey, berizalkonium chloride, triclosan (2, 4, 4′-tricloro-2′-hydroxydiphenylether), and silyl quarternary ammonium salt (octadecyl demethyl trimethoxysilyl propyl ammonium chloride).

35 . The processed tissue matrix of claim 34 , wherein the nanocrystalline silver lacks atomic disorder.

36 . (canceled)

Assignments (2)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 057112/0677 →
SECURITY INTEREST Recorded Jun 19, 2018
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 046392/0242 →